Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 5Gynecologic 4Thoracic 3Gastrointestinal 3Dermatologic 3Breast 3Sarcoma 2Plasma cell 1Head & Neck 1CNS 1

Conditions

Melanoma 68Skin Neoplasms 15Neoplasm Metastasis 14Lymphoma, T-Cell, Cutaneous 9Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 8Neoplasms 7Lymphoma 7Ovarian Neoplasms 6Mycosis Fungoides 6Kidney Neoplasms 6Colorectal Neoplasms 6Carcinoma, Merkel Cell 6Uveal Melanoma 5Uterine Cervical Neoplasms 5Sezary Syndrome 5Multiple Myeloma 5Esophageal Neoplasms 5Carcinoma, Hepatocellular 5Stomach Neoplasms 4Sarcoma, Synovial 4Pancreatic Neoplasms 4Lung Neoplasms 4Head and Neck Neoplasms 4Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Lymphoma, Non-Hodgkin 3

Interventions

pembrolizumab 12Nivolumab 10cemiplimab 5avelumab 5Ipilimumab 5atezolizumab 4poly ICLC 3fludarabine 3durvalumab 3Gemcitabine 3Cyclophosphamide 3Biopsy 3utomilumab 2ulixertinib 2pertuzumab 2osimertinib 2aldesleukin 2Trastuzumab 2Standard of Care 2Sirolimus 2Radiosurgery 2Psychiatric Rehabilitation 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Immunoglobulin G 2Docetaxel 2Disulfides 2Blood Specimen Collection 2zimberelimab 1vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × fludarabine × Dermatologic × Clear all
NCT02869217 2025-12-03

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

University Health Network, Toronto

Phase 1 Active not recruiting
22 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 14 charts
BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT02457650 2016-08-03

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Shenzhen Second People's Hospital

Phase 1 Unknown
36 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡